VPS16 Activators
VPS16 Activators comprise a diverse array of compounds that indirectly augment the functional activity of VPS16 through modulation of intracellular trafficking and endosomal-lysosomal dynamics. Compounds such as Monensin A, Bafilomycin A1, Chloroquine, and FCM Lysing solution (1x) exert their influence by altering the lysosomal pH balance. These pH changes necessitate increased endosome-lysosomal fusion, a process in which VPS16 is critically involved. The altered lysosomal function induced by these compounds, therefore, indirectly leads to an enhanced demand for VPS16's role in these fusion processes. Similarly, Wortmannin and Dynamin Inhibitor I, Dynasore, through their actions on PI3K and dynamin, respectively, modulate endosomal trafficking pathways. The inhibition of these pathways results in a compensatory increase in VPS16-mediated fusion processes, as the cell adjusts to the altered endosomal dynamics. This indirect enhancement of VPS16's activity is a critical response to the disruptions caused by these inhibitors.
Furthermore, compounds like U 18666A, YM201636, and 5-(N-Ethyl-N-isopropyl)-Amiloride, which influence cholesterol transport, PIKfyve activity, and Na+/H+ exchange, respectively, also contribute to the increased activity of VPS16. By disrupting normal cellular processes, these compounds create a cellular environment where VPS16's role in endosomal-lysosomal fusion becomes more vital. For instance, the altered endosomal pH and cholesterol trafficking indirectly necessitate increased VPS16 activity. Additionally, Z-VAD-FMK, a pan-caspase inhibitor, indirectly promotes VPS16 activity by inhibiting apoptosis, thereby potentially increasing cellular reliance on autophagic and endosomal-lysosomal degradation pathways. Finally, Concanamycin A and Nocodazole, through their actions on V-ATPase and microtubules, respectively, further highlight the adaptive nature of cellular mechanisms that increase the demand for VPS16 activity. These compounds, by disrupting lysosomal acidification and intracellular trafficking, reinforce the importance of VPS16 in maintaining cellular homeostasis under stress conditions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin A, an ionophore, enhances the activity of VPS16 by disrupting lysosomal pH balance. This disruption can lead to an increased demand for VPS16 in endosome-lysosome fusion, indirectly enhancing its functional activity. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1, a known V-ATPase inhibitor, indirectly enhances VPS16 activity by inhibiting lysosomal acidification. This results in compensatory mechanisms involving endosomal trafficking, where VPS16 plays a critical role. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, by raising the pH in lysosomes, can indirectly enhance VPS16 activity. The alteration in lysosomal function necessitates increased endosomal-lysosomal fusion, where VPS16 is integral. | ||||||
FCM Lysing solution (1x) | sc-3621 | 150 ml | $62.00 | 8 | ||
FCM Lysing solution (1x) increases lysosomal pH, leading to enhanced VPS16 activity. VPS16 is crucial in the fusion of endosomes with lysosomes, which is increased under these altered pH conditions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly enhances VPS16 activity by affecting endosomal trafficking pathways. The inhibition of PI3K alters endosomal dynamics, increasing the requirement for VPS16-mediated fusion processes. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynamin Inhibitor I, Dynasore, a GTPase inhibitor, enhances VPS16 activity indirectly by inhibiting dynamin, which is involved in endocytic vesicle scission. This results in altered endosomal trafficking, increasing reliance on VPS16-mediated processes. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $143.00 $510.00 | 2 | |
U 18666A, an intracellular cholesterol transport inhibitor, affects lysosomal function, thereby enhancing VPS16 activity. VPS16 is critical in endosomal-lysosomal fusion, which is upregulated in response to altered cholesterol trafficking. | ||||||
5-(N-Ethyl-N-isopropyl)-Amiloride | 1154-25-2 | sc-202458 | 5 mg | $104.00 | 20 | |
5-(N-Ethyl-N-isopropyl)-Amiloride, a Na+/H+ exchange inhibitor, alters endosomal pH, thus enhancing VPS16 activity. VPS16 is crucial for endosomal-lysosomal fusion, a process that becomes more pronounced under altered pH conditions. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK, a pan-caspase inhibitor, can indirectly enhance VPS16 activity. By inhibiting apoptosis, it may increase the need for cellular clearance mechanisms, wherein VPS16 plays a significant role in endosomal-lysosomal fusion. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole, a microtubule disruptor, indirectly enhances VPS16 activity. By disrupting microtubules, it affects intracellular trafficking, increasing the demand for VPS16 in endosomal-lysosomal fusion processes. | ||||||